Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 1 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar miteycasey (30.53) Submitted: 2/28/2013 11:59:08 AM : Underperform Start Price: $2.06 PPHM Score: +39.06

speculative play

Featured Broker Partners


Advertisement